Company Description
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases.
Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure.
The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension.
The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor.
PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Founded | 2002 |
| IPO Date | Oct 18, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Jonathan P. Mow MBA |
Contact Details
Address: 1 Great Valley Parkway, Suite 30 Malvern, Pennsylvania 19355 United States | |
| Phone | (610) 981-6500 |
| Website | phasebio.com |
Stock Details
| Ticker Symbol | PHASQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001169245 |
| ISIN Number | US7172241090 |
| Employer ID | 03-0375697 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jonathan P. Mow MBA | President, Chief Executive Officer and Director |
| Dr. John S. Lee M.D., Ph.D. | Chief Medical Officer |
| Lawrence R. Perkins | Chief Restructuring Officer and Principal Financial Officer |
| Susan Elizabeth Arnold Ph.D. | Senior Vice President of Technical Operations |
| Kristopher L. Hanson | SVice President, General Counsel and Corporate Secretary |
| Glen G. Burkhardt | Senior Vice President of Human Resources |
| Jonathan J. Birchall | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 12, 2024 | 8-K | Current Report |
| Nov 29, 2023 | 8-K | Current Report |
| Nov 15, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Oct 3, 2023 | 8-K | Current Report |
| Sep 27, 2023 | 8-K | Current Report |
| Aug 25, 2023 | 8-K | Current Report |
| Aug 25, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Jun 30, 2023 | 8-K | Current Report |
| May 30, 2023 | 8-K | Current Report |